Plenary Lecture
Day 1, June 10（Wed.） 9:40-10:30 Room A (5F 503)
- 1A-PL-0940
Application of Mass Spectrometry to Biomarker Development
(Natl. Inst. Health Sci.)
oYoshiro Saito, Kosuke Saito
This lecture first outlines the definition and utility of biomarkers, as well as the two essential aspects required for their development as drug developmental tools. Next, we introduce the contents of the points to consider document on evaluation of the analytical validity of biomarkers using mass spectrometry. Finally, we present examples of biomarker candidate identification using mass spectrometry. We found that the lysophosphatidylcholine 14:0 could mostly discriminate between acute and recovery phases of drug-induced lung disease (dILD) and also acute phase of dILD from other related lung diseases except for bacterial pneumonia. Besides three biomarker candidates including pyroglutamylglycine had highly differentiating ability between acute phase of mixed/cholestatic drug-induced liver injury (DILI) and its recovery phase.